Bet bromodomain

製品コード	製品名称	製品説明	文献中Selleckの製品使用例
S1021	Dasatinib	Dasatinibは新規の強力なマルチターゲット阻害剤であり、cell-free assy における Abl, Src および c-Kit に対する IC50 はそれぞれ < 1 nM, 0.8 nM および 79 nM です。Dsatinib はオートファジー (autophagy) とアポトーシス (apoptosis) を誘発し、抗腫瘍活性を示します。	Cancer Cell, 2025, S1535-6108(25)00070-4 Nat Commun, 2025, 16(1):4069 Cell Rep Med, 2025, 6(9):102310
S8762	dBET6	dBET6 is a highly cell-permeable PROTAC degrader of BET bromodomains with an IC50 of 14 nM for BRD4 binding. dBET6 also induces c-MYC downregulation and apoptosis.	J Nanobiotechnology, 2024, 22(1):692 J Pathol, 2024, 262(1):37-49 Genes Cancer, 2023, 10.18632/genesandcancer.233
S9648	NEO2734 (EP31670)	NEO2734 (EP31670) is a novel, orally active and selective dual inhibitor of p300/CBP and BET bromodomain with IC50 of both <30 nM.	Cell Rep Med, 2024, 5(3):101471 Nat Cancer, 2023, 4(10):1508-1525 PLoS Pathog, 2023, 19(8):e1011598
S6993	(+)-JQ1 carboxylic acid	(+)-JQ1 carboxylic acid ((+)-JQ1-COOH) is a (+)-JQ1 with a carboxylic acid functional group. (+)-JQ1 carboxylic acid ((+)-JQ1-COOH) can be used as a precursor to a PROTAC that targets BET bromodomains after conjugation to a linker and E3 ligase ligand.	J Immunother Cancer, 2023, 11(4)e006070 J Immunother Cancer, 2023, 11(4)e006070
S1021	Dasatinib	Dasatinibは新規の強力なマルチターゲット阻害剤であり、cell-free assy における Abl, Src および c-Kit に対する IC50 はそれぞれ < 1 nM, 0.8 nM および 79 nM です。Dsatinib はオートファジー (autophagy) とアポトーシス (apoptosis) を誘発し、抗腫瘍活性を示します。	Cancer Cell, 2025, S1535-6108(25)00070-4 Nat Commun, 2025, 16(1):4069 Cell Rep Med, 2025, 6(9):102310
S9648	NEO2734 (EP31670)	NEO2734 (EP31670) is a novel, orally active and selective dual inhibitor of p300/CBP and BET bromodomain with IC50 of both <30 nM.	Cell Rep Med, 2024, 5(3):101471 Nat Cancer, 2023, 4(10):1508-1525 PLoS Pathog, 2023, 19(8):e1011598

BET

BET製品